Key Takeaway: GSK, a partner of Ionis, has received approval from Japan's Ministry of Health for Hibsago (bepirovirsen) as the first and only functional cure for chronic hepatitis B. This landmark decision marks a significant milestone in the treatment landscape for hepatitis B, offering new hope for patients in Japan. The approval underscores the successful collaboration between Ionis and GSK.
Market Sentiment Analysis
POSITIVE FACTORS
Hibsago is approved as the first functional cure for chronic hepatitis B in Japan.
The approval represents a significant advancement in hepatitis B treatment.
This achievement highlights the collaboration between Ionis and GSK.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.1%
average across 11 past catalysts
Lead asset
ISIS 113715
Phase 2 · Type 2 Diabetes Mellitus
Full Press Release Details
Ionis partner GSK announces Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B August 24, 2026 – Ionis partner GSK today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Hibsago (bepirovirsen) as a functional cure for
Frequently Asked Questions
What is Hibsago?
Hibsago (bepirovirsen) is a treatment approved as a functional cure for chronic hepatitis B.
Who announced the approval of Hibsago?
The approval of Hibsago was announced by GSK, a partner of Ionis.
When was Hibsago approved in Japan?
Hibsago was approved in Japan on August 24, 2026.
What does the approval of Hibsago signify?
It signifies a significant advancement in the treatment of chronic hepatitis B.